BioXcel Therapeutics (BTAI) Reiterated at Buy by Truist, Continue to see 701 as Monetizable Opportunity

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $125.00 price target on BioXcel Therapeutics (NASDAQ: BTAI) on recent poster presentations.

The analyst quotes: "BioXcel announced two posters to be presented at the 2022 ASCO-GU Symposium on February 17, 2022 (details below). We believe updated results show signs of 701 efficacy in two prostate cancer subtypes and support validation of BioXcel’s AI engine that identified 701. We continue to see 701 as a monetizable opportunity given the company has said it will likely not develop and commercialize the asset on their own, and could be a source of non-dilutive financing, upside to our estimates"

For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.

Shares of BioXcel Therapeutics closed at $17.59 yesterday.

Written by Vlad Schepkov | [email protected]

You May Also Be Interested In

• Packaging Corp. of America (PKG) PT Raised to $292 at UBS Following Containerboard Price Increase
• Brinker Int'l (EAT) PT Raised to $260 at DA Davidson, Neutral Rating Maintained
• Lake Street Starts RF Industries Ltd. (RFIL) at Buy